Friday November 27 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

FinnBrit Consulting

Pharmaceutical products have complex and extended development cycles with an absolute minimum of at least five years for a new innovator product, and more than 3 years for a generic drug. Every extra day prior to launch costs money!

FinnBrit Consulting has the necessary experience to guide you through your drug development program beginning with preformulation and their subsequent process design, development and manufacturing to the eventual launch of the finished medicinal product.

Drug formulation has traditionally been considered the Cinderella of drug development. There are numerous pitfalls that must be avoided. The formulation must be stable, since a future stability problem results not only, in an additional cost for a new formulation, but also the cost of the delayed launch of the product. Development projects have failed because of an inability to provide a stable, effective drug product.

An inadequate patent may result in a future loss of an infringement suit against a competitor. An inadequate understanding of the regulatory framework may lead to additional delays because of the need to answer supplementary questions from the regulatory agency and/or provide additional data.

In the same way that formulation is the Cinderella of drug development; excipients are the Cinderellas of formulation design. They do not treat any disease, but without them we cannot provide a formulation for any drug. Excipients are at the core of formulation design, and formulation scientists need to understand them very well. Poor understanding of the advantages and limitations of excipients can lead to poor formulations and costly delays.

In some cases you may be able to eventually save a failed project through additional costly trials or tests. However, the better the initial understanding of the integrated process of drug development, the less costly it will be.

FinnBrit Consulting provides timely advice on all aspects of drug development and excipients that reduce time lines and prevents pitfalls. Always remember that each extra day prior to launch costs money!


Contact Details:
Waltham
MA
United States of America
Tel:781.894.2572
Fax:
Email:consulting@finnbrit.com
WWW:

www.finnbrit.com/




BioNews Results for FinnBrit Consulting:

EMBO Appoints Bernd Pulverer as Head of Scientific Publication
Bionity.com:  Nov 23 2009 6:33AM Matching: consulting
PAREXEL Experts to Discuss Impact of Pharmacovigilance Trends on Biosimilars and Generics at World Generic Med
PR Newswire:  Nov 23 2009 12:43AM Matching: consulting
Panel: Health IT professional shortfall underestimated
Cardiovascular Business:  Nov 21 2009 4:04AM Matching: consulting
Whats Your Role in Big Practice Transitions?
Physicians Practice:  Nov 21 2009 11:57AM Matching: consulting
'Deep' Sequencing to Identify Treatment-Experienced Patients Who Respond to Maraviroc (MVC)
National AIDS Treatment Advocacy Project:  Nov 21 2009 12:27AM Matching: consulting
Promote your company here: BioNewsCast - Press Release Distribution

View more FinnBrit Consulting news.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 91 times since April 2007, the link to the organisation's website has been followed 17 times

Recent Search Terms used to find this page: finnbrit society | .

Search for more companies in Waltham

Search for more companies in MA



This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for FinnBrit Consulting

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.